Replies to post #141867 on Biotech Values

[mcbio]

I have not been following RIGL closely for the past 2 years. But, I do know that Mike Weinblatt, MD and past president of the American College of Rheumatology, is an advisor for fostamatinib clinical trials. He is well-versed in the agency requirements as he has been involved in both TNF sequesterer trials and B-cell relevant RA studies (with abatacept).

So, I can only conclude that one of the registration studies will have a radiographic endpoint.

Thanks for the response. I don't follow RIGL as closely as I used to. Jq and I discussed on here before how their initial pivotal fostamatinib trial to read out is probably the one that is most likely to fail (http://investorshub.advfn.com/boards/replies.aspx?msg=64248505 ) and I thought, given their pipeline and cash, there could be a buying opportunity if that happened. However, given some of the buzz surrounding the other RA players, in particular Galapagos, I'm not really as interested as RIGL as I used to be.